NYSEAMERICAN:TOVX Theriva Biologics (TOVX) Stock Price, News & Analysis $0.23 0.00 (0.00%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$0.23▼$0.2350-Day Range N/A52-Week Range$0.20▼$0.94Volume77,399 shsAverage Volume169,654 shsMarket Capitalization$3.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesShort Interest Get Theriva Biologics alerts: Email Address Ad Behind the MarketsThe Only Retirement Stock You'll Ever Need? Discover NowThere is a little region of America called Loudoun County. The value of each square mile has shot up close to $10 billion... It's also the source of the single greatest investment opportunity of our generation...Get all the urgent details here >>> About Theriva Biologics Stock (NYSEAMERICAN:TOVX)Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.Read More TOVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TOVX Stock News HeadlinesMay 23, 2024 | msn.comTheriva gets FDA fast track status for VCN-01 for pancreatic cancerMay 23, 2024 | globenewswire.comTheriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic CancerJuly 4, 2024 | Behind the Markets (Ad)[BUY ALERT] “This Could Be Worth 28X More than NVIDIA”This firm's stock is currently trading for only $15. But that won't last long. Because even OpenAI founder Sam Altman admits AI "depends" on this firm's work.May 17, 2024 | finance.yahoo.comTheriva Biologics, Inc. (TOVX)May 14, 2024 | globenewswire.comTheriva™ Biologics to Participate in the A.G.P. Virtual Healthcare ConferenceMay 7, 2024 | investorplace.comTOVX Stock Earnings: Theriva Biologics Beats EPS for Q1 2024May 7, 2024 | globenewswire.comTheriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial ResultsApril 25, 2024 | investing.comTheriva reports progress in retinoblastoma treatment trialJuly 4, 2024 | Behind the Markets (Ad)[BUY ALERT] “This Could Be Worth 28X More than NVIDIA”This firm's stock is currently trading for only $15. But that won't last long. Because even OpenAI founder Sam Altman admits AI "depends" on this firm's work.April 25, 2024 | globenewswire.comTheriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2024 | globenewswire.comTheriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory RetinoblastomaApril 22, 2024 | globenewswire.comTheriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual MeetingApril 17, 2024 | benzinga.comTheriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat CancersApril 8, 2024 | finanznachrichten.deTheriva Biologics, Inc.: Theriva Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual MeetingApril 8, 2024 | globenewswire.comTheriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual MeetingMarch 27, 2024 | seekingalpha.comTheriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | finance.yahoo.comQ4 2023 Theriva Biologics Inc Earnings CallMarch 25, 2024 | globenewswire.comTheriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial ResultsMarch 22, 2024 | benzinga.comPreview: Theriva Biologics's EarningsMarch 19, 2024 | finanznachrichten.deTheriva Biologics, Inc.: Theriva Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsMarch 19, 2024 | globenewswire.comTheriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsMarch 11, 2024 | globenewswire.comTheriva™ Biologics to Participate in the BIO-Europe Spring ConferenceFebruary 8, 2024 | msn.comTheriva Biologics Reports Positive Phase 2b Trial ProgressFebruary 8, 2024 | msn.comTheriva Biologics VIRAGE Trial Progresses PositivelyFebruary 7, 2024 | finance.yahoo.comTheriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal AdenocarcinomaJanuary 16, 2024 | finance.yahoo.comTheriva Biologics to Participate in the B. Riley Securities Annual Oncology ConferenceNovember 20, 2023 | finance.yahoo.comTheriva Biologics, Inc. (NYSE:TOVX) Q3 2023 Earnings Call TranscriptSee More Headlines Receive TOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theriva Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:TOVX CUSIPN/A CIKN/A Webtherivabio.com Phone(301) 417-4364Fax301-417-4367Employees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.28% Return on Assets-32.97% Debt Debt-to-Equity Ratio0.01 Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book0.11Miscellaneous Outstanding Shares17,280,000Free Float16,367,000Market Cap$3.97 million OptionableNot Optionable Beta1.38 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Steven A. Shallcross CPA (Age 63)CEO, CFO, Treasurer, Corporate Secretary & Director Comp: $993.46kDr. Vince Wacher Ph.D.Head of Product & Corporate DevelopmentDr. Michael Kaleko M.D.Ph.D., Senior Vice President of Research & DevelopmentDr. Ramon Alemany Ph.D.Senior VP of Discovery & Chairman of Scientific Advisory BoardMs. Lara M. GuzmanSenior Director of Project OperationsKey CompetitorsSensei BiotherapeuticsNASDAQ:SNSETalpheraNASDAQ:TLPHCara TherapeuticsNASDAQ:CARABioxytranOTCMKTS:BIXTKintara TherapeuticsNASDAQ:KTRAView All Competitors TOVX Stock Analysis - Frequently Asked Questions Are investors shorting Theriva Biologics? Theriva Biologics saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 584,300 shares, a drop of 14.5% from the May 31st total of 683,200 shares. Based on an average daily trading volume, of 565,000 shares, the short-interest ratio is currently 1.0 days. Approximately 3.5% of the shares of the stock are sold short. View Theriva Biologics' Short Interest. How were Theriva Biologics' earnings last quarter? Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) released its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter. How do I buy shares of Theriva Biologics? Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:TOVX) was last updated on 7/4/2024 by MarketBeat.com Staff From Our PartnersOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredThe End of Privacy for Americans… Get Out of Cash Now!Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.Golden Crest | SponsoredRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theriva Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.